Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Supreme Court refuses...

    Supreme Court refuses interim order on sale of Fortis shares to IHH; final hearing on February 26

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-02-16T12:33:12+05:30  |  Updated On 16 Aug 2021 2:10 PM IST

    A bench comprising Chief Justice Ranjan Gogoi and Justice Sanjiv Khanna said that it would accord final hearing in the case on February 26.


    New Delhi: The fate of the Fortis and IHH deal is finally going to be decided on February 26 as the apex court recently informs about the final hearing. The Supreme Court Friday refused to pass any interim order on pleas relating to the sale of controlling stakes of Fortis Healthcare to Malaysian IHH Healthcare Berhad by former Ranbaxy promoters and hospital operators -- Malvinder and Shivinder Singh.


    A bench comprising Chief Justice Ranjan Gogoi and Justice Sanjiv Khanna said that it would accord final hearing in the case on February 26.


    Read Also: Fortis Healthcare, Fortis Hospitals to recover Rs 403 crore from Singh brothers and 7 others: SEBI


    The apex court was hearing the plea of Japanese firm Daiichi Sankyo which is seeking to recover Rs 3,500 crore, awarded to it by a Singapore tribunal in its case against Malvinder and Shivinder Singh.


    The Japanese firm, which has filed the contempt plea against the Singh brothers in the apex court, has said that it was promised some shares of Fortis Healthcare by the Singh brothers.


    "Instead of passing any order on the interlocutory applications, we fix the matter for final disposal on February 26 at the top of the Board," the bench said.


    Read Also: Fortis Healthcare CEO Bhavdeep Singh quits


    The apex court, on December 14 last year, had ordered status quo with regard to the sale of controlling stakes of Fortis Healthcare.


    "Status quo with regard to the sale of the controlling stake in Fortis Healthcare to Malaysian IHH Healthcare Berhad be maintained," the bench had said.


    The top court had also issued notices to the Singh brothers asking them to explain as to why contempt proceedings are not initiated against them for allegedly violating its earlier order by pledging the shares.


    The board of Fortis Healthcare had approved in July a proposal from IHH Healthcare to invest Rs 4,000 crore by way of preferential allotment for a 31.1 per cent stake.


    Read Also: Singh brothers, 8 other entities told to repay over Rs 403 crore to Fortis Healthcare: SEBI


    The Malaysian IHH Healthcare Bhd became the controlling shareholder of Fortis Healthcare Ltd by acquiring a 31.1 per cent stake in the company.


    Daiichi had bought Ranbaxy in 2008. Later, it had moved the Singapore arbitration tribunal accusing that the Singh brothers had concealed information that Ranbaxy was facing a probe by the US Food and Drug Administration and the Department of Justice while selling its shares.


    Read Also: Former Fortis Healthcare promoter Shivinder Singh sues brother Malvinder, ends business ties


    Daiichi had to enter into a settlement agreement with the US Department of Justice, agreeing to pay USD 500 million penalties to resolve potential, civil and criminal liability.


    The company had then sold its stake in Ranbaxy to Sun Pharmaceuticals for Rs 22,679 crore in 2015.

    Chief Justice Ranjan GogoidaiichiDaiichi SankyoFinal hearingFortis sharesinterim orderinterlocutory applicationsJapanese firm Daiichi SankyoJustice Sanjiv KhannaMalaysian firmMalaysian IHH HealthcareMalvinderRanbaxyRanbaxy laboratoriesSCShivinder SinghSingh brothersSun PharmaceuticalsSupreme CourtUS Food and Drug AdministrationUSD
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok